SCB-1022

Clover Biopharmaceuticals AUS Pty · Phase 1 active Biologic

At a glance

Generic name	SCB-1022
Sponsor	Clover Biopharmaceuticals AUS Pty
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SCB-1022 CI brief — competitive landscape report
SCB-1022 updates RSS · CI watch RSS
Clover Biopharmaceuticals AUS Pty portfolio CI